Boston, MA -- (SBWIRE) -- 05/20/2016 -- In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis, non-hematological cancers are thought to account for 94% of global cancer prevalence. The key cancer indications of this report, namely breast, colorectal, lung and prostate cancer, constitute approximately 51% of global cancer prevalence.

The risk of cancer increases greatly in patients over the age of 65. As populations are projected to increase, with aging and increasing incidence of obesity, the prevalence of cancer as a genetic disease is only anticipated to increase, thereby acting as a driver for revenue growth.  Typically, chemotherapy has curative or palliative uses depending on whether the patient’s tumors are resectable or unresectable, respectively; however, use of chemotherapies is often reliant on performance status, which is lacking in many cancer patients.

There has been a shift towards developing targeted therapies, which by their nature have less toxicity associated with their use and as a result can be administered to greater numbers of cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.

Get More Details on this Report and a Full Table of Contents at Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics

Report Scope

Global revenues for the non-hematological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.86%, from $73 billion in 2014 to $141 billion in 2021

-What is the generic penetration?
-Which drugs will achieve blockbuster status?

Overall, there are 6,484 oncology products in the pipeline, which make it the largest therapy area pipeline

-How does the composition of the pipeline compare with that of the existing market?
-What mechanisms of action are most common for pipeline drugs?

18 of the top 20 pharmaceutical companies will market non-hematological cancer drugs in the forecast period

-How is their revenue share of the non-hematological cancer market set to change?
-What CAGR will these companies register in the forecast period?

Reasons to Get this Report

This report will allow you to -

-Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis

-Visualize the composition of the non-hematological cancer market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players

-Analyze the non-hematological cancer pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications

-Understand the growth in patient epidemiology and market revenues for the non-hematological cancer market globally and across the key players and product types

-Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various non-hematological cancers

-Identify commercial opportunities in the non-hematological cancer deals landscape by analyzing trends in licensing and co-development deals

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:
-Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence
-Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence
-Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments
-Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments
-Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics